Company Contact
Steve Berens
Executive Vice President
email: steveberens@pertzye.com
Digestive Care, Inc.
1120 Win Drive
Bethlehem, PA 18017
Phone: 1-877-882-5950
email: questions@pertzye.com
Digestive Care News Releases
- Digestive Care, Inc. Announces FDA Approval of a 24,000 USP Lipase Units Capsule of PERTZYE® (pancrelipase) Delayed Release Capsules to Treat Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis and Other Conditions 07/14/2017
- Digestive Care, Inc. Announces FDA Labeling Revision Approval for PERTZYE® (pancrelipase) Administering PERTZYE® through a gastrostomy tube 07/12/2017
- Digestive Care, Inc. Announces FDA Approval of Infant–Specific Dose of PERTZYE® (pancrelipase) Delayed-Release Capsules to Treat Exocrine Pancreatic Insufficiency (EPI) Due to Cystic Fibrosis 10/10/2016
- Digestive Care, Inc. Donates Year-Long Supply of PERTZYE® (pancrelipase) to Cystic Fibrosis Patients in El Salvador 03/23/2014
- Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE® (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis 05/09/2013
- Digestive Care, Inc. Launches a Co-Pay Assistance Program in Cooperation with CF Services Pharmacy 12/10/2012
- Digestive Care Inc. Announces FDA Approval of PERTZYE® (pancrelipase) Delayed-Release Capsules 5/18/2012